Who are Nucleotidic or Nucleosidic Treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nucleos(t)tide analogues, Tenofovir/Emtricitabine, Telbivudine, Lamivudine, Adefovir ,Enecavir, Emtricitabine and Tenofovir, Emtricitabine / Tenofovir, Emtricitabine/tenofovir disoproxil fumarate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nucleotidic-or-nucleosidic-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nucleotidic or Nucleosidic Treatment — Competitive Intelligence Brief

Nucleotidic or Nucleosidic Treatment (Nucleotidic or Nucleosidic Treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI). Area: Infectious Disease; Virology.

phase 3 Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) Viral reverse transcriptase; viral polymerase Infectious Disease; Virology Small molecule Live · refreshed every 30 min

Target snapshot

Nucleotidic or Nucleosidic Treatment (Nucleotidic or Nucleosidic Treatment) — ANRS, Emerging Infectious Diseases. Nucleotidic or nucleosidic compounds inhibit viral reverse transcriptase and/or other viral enzymes to suppress replication of retroviruses or other nucleic acid-dependent pathogens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Nucleotidic or Nucleosidic Treatment TARGET	Nucleotidic or Nucleosidic Treatment	ANRS, Emerging Infectious Diseases	phase 3	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI)	Viral reverse transcriptase; viral polymerase
Nucleos(t)tide analogues	Nucleos(t)tide analogues	King Abdullah International Medical Research Center	marketed	Nucleos(t)ide reverse transcriptase inhibitor / Nucleos(t)ide polymerase inhibitor	Viral reverse transcriptase; viral polymerase
Tenofovir/Emtricitabine	Tenofovir/Emtricitabine	Bristol-Myers Squibb	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV reverse transcriptase
Telbivudine, Lamivudine, Adefovir ,Enecavir	Telbivudine, Lamivudine, Adefovir ,Enecavir	Shao-quan Zhang	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI)	Hepatitis B virus reverse transcriptase
Emtricitabine and Tenofovir	Emtricitabine and Tenofovir	Puerto Rico Community Network for Clinical Research on AIDS	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Emtricitabine / Tenofovir	Emtricitabine / Tenofovir	The Miriam Hospital	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV reverse transcriptase
Emtricitabine/tenofovir disoproxil fumarate	Emtricitabine/tenofovir disoproxil fumarate	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) class)

ANRS, Emerging Infectious Diseases · 1 drug in this class
Shao-quan Zhang · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nucleotidic or Nucleosidic Treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/nucleotidic-or-nucleosidic-treatment. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab